Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, Canzonieri V, Sorio R, Alder H, Wernicke D, Stoppacciaro A, Baldassarre G, Croce CM. Vecchione A, et al. Among authors: losito s. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9845-50. doi: 10.1073/pnas.1305472110. Epub 2013 May 22. Proc Natl Acad Sci U S A. 2013. PMID: 23697367 Free PMC article.
Significance of erb-B2 immunoreactivity in cervical cancer.
Califano D, Losito S, Pisano C, Santelli G, Greggi S, Iodice F, DiVagno G, Silvestro G, Tambaro R, Formato R, Iaffaioli VR, Di Maio M, Pignata S. Califano D, et al. Among authors: losito s. Front Biosci. 2006 Sep 1;11:2071-6. doi: 10.2741/1949. Front Biosci. 2006. PMID: 16720293
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. Pisano C, et al. Among authors: losito s. Cancer Chemother Pharmacol. 2009 Oct;64(5):1021-7. doi: 10.1007/s00280-009-0958-0. Epub 2009 Mar 6. Cancer Chemother Pharmacol. 2009. PMID: 19266200 Clinical Trial.
BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.
Chiappetta G, Basile A, Arra C, Califano D, Pasquinelli R, Barbieri A, De Simone V, Rea D, Giudice A, Pezzullo L, De Laurenzi V, Botti G, Losito S, Conforti D, Turco MC. Chiappetta G, et al. Among authors: losito s. J Clin Endocrinol Metab. 2012 Jan;97(1):E115-20. doi: 10.1210/jc.2011-0484. Epub 2011 Nov 9. J Clin Endocrinol Metab. 2012. PMID: 22072743
79 results